Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

被引：4

作者：

Chow, Laura Quan Man

Mehra, Ranee

Haddad, Robert I.

Mahipal, Amit

Weiss, Jared

Berger, Raanan

Eder, Joseph Paul

Burtness, Barbara

Tahara, Makoto

Keam, Bhumsuk

Le, Dung T.

Muro, Kei

Geva, Ravit

Chung, Hyun Cheol

Lin, Chia-Chi

Ayers, Mark

Aurora-Garg, Deepti

Lunceford, Jared K.

Cheng, Jonathan D.

Seiwert, Tanguy Y.

机构：

[1] Seattle Canc Care Alliance, Seattle, WA USA

[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[6] Sheba Med Ctr, Tel Hashomer, Israel

[7] Yale Canc Ctr, New Haven, CT USA

[8] Natl Canc Ctr Hosp East, Chiba, Japan

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] Johns Hopkins Univ, Baltimore, MD USA

[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[12] Sourasky Med Ctr, Tel Aviv, Israel

[13] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[14] Natl Taiwan Univ Hosp, Taipei, Taiwan

[15] Merck & Co Inc, Kenilworth, NJ USA

[16] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.6010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6010

引用

页数：3